Pluri Inc.
PLURHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePluri Inc., a biotechnology company, engages in the research, development, and manufacture of cell-based products, cell therapeutics, and related technologies for various industries. With a market capitalization of $12.5M, it sits in micro-cap territory. The company develops placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions; and an immunotherapy platform.
Market Cap
$12.5M
Beta
0.69
P/E (TTM)
—
P/E (Fwd)
-0.52
EPS (TTM)
$-2.44
EPS (Fwd)
$-1.90
ROE
—
ROA
-49.0%
Cash
$7.8M
Total Debt
$34.9M
Free CF
-$12.1M
52W Change
-74.6%
Annual Financials
Cash vs Debt
Where PLUR stands vs its 150-day and 200-day moving averages
As of the October 5, 2026 close, PLUR finished 57.02% below its 150-day moving average ($2.35) and 61.00% below its 200-day moving average ($2.59). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is PLUR overbought or oversold?
At the October 5, 2026 close, PLUR's RSI(14) was 23.3, in oversold territory (below 30). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
On the balance sheet, PLUR has $7.8M in cash with $34.9M in obligations. The ability to service this debt comfortably depends on continued operational cash generation. Free cash flow is running at -$12.1M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Revenue has grown from $287K (2023) to $1.0M (2026), reflecting a 254% increase over the period.
The relatively low beta of 0.69 suggests PLUR is a less volatile holding compared to the broader index. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Pluri Inc.'s trajectory.